Prosecution Insights
Last updated: November 08, 2026
Application No. 19/543,832

COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS

Final Rejection §103§DP
Filed
Feb 18, 2026
Priority
Mar 28, 2024 — provisional 63/571,351 +5 more
Examiner
NEAGU, IRINA
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Model Medicines Inc.
OA Round
2 (Final)
47%
Grant Probability
Moderate
3-4
OA Rounds
2y 0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
337 granted / 720 resolved
-13.2% vs TC avg
Strong +57% interview lift
Without
With
+57.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
65 currently pending
Career history
786
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
39.5%
-0.5% vs TC avg
§102
11.5%
-28.5% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 720 resolved cases

Office Action

§103 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Applicant’s amendment of 12 August 2026, in which claims 1, 14, 22 have been amended, claims 2-3, 15-16 have been cancelled, and new claims 23-26 have been added, is acknowledged. Claims 1, 4-14, 17-26 are pending in the application. Claims 1, 4-14, 17-26 are being examined on their merits herein. Information Disclosure Statement The information disclosure statement (IDS) submitted on 12 August 2026 is acknowledged and considered. Response to arguments of 12 August 2026 In view of Applicant’s amendment of 12 August 2026, all the rejections to claims 2-3, 15-16 are herein withdrawn. Claims 2-3, 15-16 have been cancelled. In view of Applicant’s amendment of 12 August 2026, the objection to claim 22 is herein withdrawn. Applicant has clarified the claim language. Applicant’s arguments (Remarks of 12 August 2026, pages 6-11) against the rejection of claims 1-22 under 35 U.S.C. 103 over Nicola, have been considered. Applicant argues (page 7) that the instant Specification presents pipendoxifen’s anti-viral activity against hepatitis C virus, novovirus, Influenza A and B viruses, and coronaviruses 229E and OC43. The data is acknowledged. Applicant submits a literature reference by Jeon and seems to compare the IC50 for bazedoxifene in Jeon with “Nicola’s criteria”. Applicant’s argument that Jeon’s data “does not satisfy Nicola’s candidate criteria” is confusing. A person of ordinary skill in the art, reading Jeon, would notice that remdesivir, the FDA approved drug for treating SARS-CoV-2 infection, has a modest IC50 = 11.41 mM and a SI = 2.19 based on data in Fig. 1, Jeon page 3. That is why Applicant’s argument (page 8) that bazedoxifene, which has an IC50 = 3.44 mM and a SI = 4.35 in the very same assay as remdesivir (Jeon, page 6), falls below some criteria allegedly stated by Nicola, is not persuasive. Ultimately, remdesivir was used to treat human patients infected with SARS-CoV-2 virus, even though the in vitro antiviral data obtained by Jeon for remdesivir was less convincing than for other drugs tested. The instant claims are drawn to a method of treating an infection caused by an RNA virus; the antiviral activity is measured by IC50 (cytotoxicity is a different aspect). Both remdesivir and bazedoxifene are effective antivirals against SARS-CoV-2 infection, based on their IC50 as measured by Jeon. Applicant argues (page 8) that pipendoxifene and bazedoxifene have “differing SARS-CoV-2 profiles” and there is no reasonable expectation of success in “extrapolating” pipendoxifene’s SARS-CoV-2 activity to the recited RNA viruses. In response, this is not a case of “extrapolating”. The rejection has been re-written based on Applicant’s amendment of 12 August 2025. The amendment of 12 August 2025 removed Ebola virus as one of the RNA viruses in the claims. The idea of the first non-final rejection (of 05/13/2026) had been that Bazedoxifene and pipendoxifene were direct structural homologs and had a common mechanism as SERMs, and bazedoxifene was known to be effective against Ebola; based on this fact, the examiner had advanced a prima facie case for pipendoxifene being effective against Ebola, as well. A modified rejection is made below. The examiner maintains that a person of ordinary skill in the art would have been motivated to expand the testing of pipendoxifene against different RNA viruses, beyond SARS-CoV-2, because 1.Nicola teaches a method for treating an infection or a disease caused by a RNA virus, for example, a coronavirus, or is influenza, such as influenza A, or hepatitis C, comprising administering to a subject in need thereof a composition comprising a compound which is pipendoxifene. 2. Nicola teaches that Pipendoxifene binds to the viral protein RdRp which is vital to the viral replication process of all RNA viruses, and Nicola teaches that pipendoxifene is a RdRP inhibitor for preventing, delaying the onset of, or treating an infection or a disease caused by a RNA virus. Further, Nicola teaches that other inhibitors of RdRp are effective against RNA viruses such as hepatitis C virus, and coronaviruses. Thus, the person of ordinary skill in the art would have tested RdRP inhibitor pipendoxifene in a method of inhibiting viral activity of a RNA virus beyond SARS-CoV-2, such as hepatitis C virus, and coronaviruses, with the expectation of achieving therapeutic effect. Applicant’s arguments (page 9, page 10, first paragraph) are not persuasive. As explained above, the comparison with bazedoxifene was removed from the rejection, in view of Applicant’s amendment of 12 August 2026. Yet, on a note, a POSITA, looking at the arguments presented, would view the potencies IC50 1.24 versus 2.24 mM or 2.20 versus 3.83 mM as being similar, and certainly not “undermining any presumption that pipendoxifene would inherit bazedoxifene’s antiviral activity”. In medicinal chemistry, a compound cannot “inherit” another compound’s biological activity. Applicant argues (pages 10-11) that Applicant’s identification of the Thumb-1 allosteric site of RdRp as the binding site for pipendoxifene, together with Applicant’s demonstration that pipendoxifene exhibits antiviral activity across the recited RNA viruses, represents an unexpected property not disclosed by Nicola. In response, this argument is not persuasive. Nicola teaches [0533] that Pipendoxifene binds to the viral protein RdRp (EC50 = 8.42 mM). The mechanism of binding, allosteric at the Thumb-1 site, is inherent. Nicola teaches that RdRp is vital to the viral replication process of all RNA viruses. Nicola teaches [0501] RdRp is a core replication/transcriptional element of all RNA viruses. Thus, by teaching that pipendoxifene is an inhibitor of RdRP, Nicola implicitly teaches that pipendoxifene reduces or inhibits viral replication of the RNA virus, as in instant claims 12, 14, 20. Nicola teaches that [0502] RdRp’s crucial role in the life cycle of RNA viruses has led to its targeted inhibition for a number of viral infections such as hepatitis C virus, and coronaviruses, which are RNA viruses other than SARS-CoV-2, as in the instant claims 1, 4-5, 14, 17-18. For all these reasons, the rejection of the claims under 35 U.S.C. 103 over Nicola is maintained, and a modified rejection is made below. In view of Applicant’s amendment of 12 August 2026, the rejection of claims 1-2, 5-15, 18-22 under 35 U.S.C. 103 over Cooper and Nicola is herein withdrawn. Applicant has amended independent claims 1, 14 to recite that the RNA virus is selected from the group consisting of an influenza A virus, an influenza B virus, a hepatitis C virus, a norovirus, and a coronavirus other than SARS-CoV-2. Zaire ebolavirus (EBOV) and Marburg virus (MARV) (Cooper) are no longer encompassed by the claims. A modified rejection to the claims under 35 U.S.C. 103 is made over Hong and Nicola, based on Applicant’s amendment of 12 August 2026. Applicant argues (page 13) that Hong teaches raloxifene, which is structurally unrelated to the instant pipendoxifene, and Hong provides no rationale to select pipendoxifene from Nicola’s disclosure. In response, the rejection is not based on similarity of structure, but rather on the common mechanism, as SERMs, of pipendoxifene and raloxifene, and the teaching that SERM raloxifene has antiviral activity against influenza A or hepatitis C virus. The person of ordinary skill in the art would have been motivated to test pipendoxifene against influenza A or hepatitis C virus, because Hong and Nicola teach that pipendoxifene is a SERM modulator, and Hong teaches that SERM modulator raloxifene demonstrates efficacy in treating viral infections caused by influenza A and hepatitis C viruses. Thus, the person of ordinary skill in the art would have tested SERM modulator pipendoxifene against influenza A or hepatitis C virus, with the expectation that pipendoxifene has antiviral activity against these viruses. In view of Applicant’s amendment of 12 August 2026, the rejection of claims 1-3, 5-16, 18-22 under 35 U.S.C. 103 over Serafim and Nicola is herein withdrawn. Serafim teaches treating an infection caused by RNA virus yellow fever virus (YFV), which is no longer encompassed by the claims. Applicant argues (page 15) against the rejection of the claims under the judicially created doctrine of obviousness type double patenting over claims of U.S. patent 12,551,475, in view of Nicola, based on arguments presented above, including arguments related to the Thumb-1 allosteric site of RdRp not being known in the prior art as a broad-spectrum antiviral target. These arguments have been addressed above. The rejection is herein maintained, and a modified rejection is made below, based on Applicant’s amendment of 12 August 2026. Applicant’s amendment of 12 August 2026 necessitated the following modified rejections below. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 4-14, 17-26 are rejected under 35 U.S.C. 103 as being unpatentable over Nicola et al. (WO 2021/247601, published 9 December 2021, cited in IDS). Nicola teaches [0018] a method for preventing, delaying the onset of, or treating an infection or a disease caused by a RNA virus, comprising administering to a subject in need thereof a composition comprising a compound which is pipendoxifene (one of 9 compounds listed). Nicola teaches [0012] that the RNA viral infection to be treated is, for example, a coronavirus, or is SARS COV-1, SARS COV-2, the common cold, influenza, SARS, hepatitis C, hepatitis E, West Nile fever, Ebola virus disease, rabies, polio and measles, or a combination thereof. [0013] Non-limiting examples of RNA viral infection include Paramyxoviruses, Hendra and Nipah viruses, Measles, Severe acute respiratory syndrome coronavirus (SARS), COVID-19, Middle east respiratory syndrome coronavirus (MERS), Picornaviruses, Poliomyelitis (‘Polio’), Hepatitis A virus (HAV), Rotavirus, Human immunodeficiency virus (HIV), Human T-cell lymphotropic virus (HTLV), Hepatitis C virus (HCV), Hepatitis E virus (HEV), Rabies, Ebola virus disease (EVD), Marburg virus, Lassa fever, Lymphocytic choriomeningitis virus (LCMV), Arboviruses (‘ARthropod-BOrne viruses’), Japanese encephalitis (JE), West Nile fever, Yellow fever, Dengue fever, Zika virus, Equine encephalitis viruses, Chikungunya, O’nyong-nyong, Bunyaviruses, Rift valley fever and Crimean-Congo haemorrhagic fever, Hantavirus, or a combination thereof. Thus, Nicola teaches that the RNA virus is an influenza virus (influenza A in [0301]), a hepatitis C virus, as in instant claim 4, which are not coronaviruses, as in instant claim 5. Nicola teaches [0023] that the subject in need is a subject that is suffering from the infection or the disease, or a subject that is at a risk for the infection or the disease, as in instant claim 7, or the subject has been exposed to the RNA virus, is suspected to have been exposed to the RNA virus, or is at a risk of being exposed to the RNA virus, as in instant claim 6. Nicola teaches [0023] that the infection or the disease is in the respiratory tract of the subject, which includes the lung, as in instant claim 8. Nicola teaches [0023] that the subject is a mammal, as in instant claim 9. Nicola teaches [0026] that the composition is administered to the subject by intravenous administration, nasal administration, pulmonary administration, oral administration, parenteral administration, or nebulization, as in instant claim 11. The composition is in the form of powder, pill, tablet, microtablet, pellet, micropellet, capsule, capsule containing microtablets, liquid, aerosols, or nanoparticles, as in instant claim 10. Nicola teaches [0028] that administrating the composition results in reduction of the viral titer of the RNA virus in the subject as compared to that in the subject before administration of the composition, as in instant claim 13. Nicola teaches [0503], Table 6 that pipendoxifene is a RdRP inhibitor for preventing, delaying the onset of, or treating an infection or a disease caused by a RNA virus. Nicola teaches [0533] that Pipendoxifene binds to the viral protein RdRp (EC50 = 8.42 mM). Nicola teaches that RdRp is vital to the viral replication process of all RNA viruses. Nicola teaches [0501] RdRp is a core replication/transcriptional element of all RNA viruses. Thus, by teaching that pipendoxifene is an inhibitor of RdRP, Nicola implicitly teaches that pipendoxifene reduces or inhibits viral replication of the RNA virus, as in instant claims 12, 14, 20. Nicola teaches that [0502] RdRp’s crucial role in the life cycle of RNA viruses has led to its targeted inhibition for a number of viral infections such as hepatitis C virus, and coronaviruses, which are RNA viruses other than SARS-CoV-2, as in the instant claims 1, 4-5, 14, 17-18. Nicola teaches [0538]-[0540] administering pipendoxifene to animals or humans, which is consistent with in vivo contacting of a cell or tissue with pipendoxifene, as in instant claim 21. By teaching [0026] pulmonary administration of a composition of the invention, Nicola implicitly teaches contacting a lung cell or tissue with a composition comprising pipendoxifene, as in instant claim 22. Nicola does not provide experimental data showing that pipendoxifene is effective to treat an infection caused by an RNA virus other than SARS-CoV-2, such as influenza A virus, or hepatitis C virus, as in the instant claims 1, 4-5, 14, 17-18, 26. Nicola does not teach treating a coronavirus which is HCoV-229E, or HCoV-OC43 with pipendoxifen, as in instant claims 24, 25. It would have been obvious to a person of ordinary skill in the art to test pipendoxifene disclosed by Nicola for inhibitory properties against RNA viruses other than SARS-CoV-2. The person of ordinary skill in the art would have been motivated to expand the testing of pipendoxifene against different RNA viruses, beyond SARS-CoV-2, because Nicola teaches a method for treating an infection or a disease caused by a RNA virus, comprising administering to a subject in need thereof a composition comprising a compound which is pipendoxifene, and Nicola teaches that the RNA viral infection to be treated is, for example, a coronavirus, or is influenza, such as influenza A, or hepatitis C. Thus, the person of ordinary skill in the art would have tested pipendoxifene against different RNA viruses, beyond SARS-CoV-2, such as against an RNA virus which is an influenza virus such as influenza A, or hepatitis C virus, or a corona virus, with a reasonable expectation that pipendoxifene is an effective antiviral against said viruses. Further, the person of ordinary skill in the art would have been motivated to test pipendoxifene against different RNA viruses, beyond SARS-CoV-2, because Nicola teaches that Pipendoxifene binds to the viral protein RdRp which is vital to the viral replication process of all RNA viruses, and Nicola teaches that pipendoxifene is a RdRP inhibitor for preventing, delaying the onset of, or treating an infection or a disease caused by a RNA virus. Thus, the person of ordinary skill in the art would have tested RdRP inhibitor pipendoxifene in a method of inhibiting viral activity of a RNA virus beyond SARS-CoV-2, with the expectation that pipendoxifene reduces or inhibits viral replication of the RNA virus and treats the infection or disease caused by said RNA virus. Furthermore, the person of ordinary skill in the art would have been motivated to test RdRP inhibitor pipendoxifene against different RNA viruses, beyond SARS-CoV-2, because Nicola teaches that other inhibitors of RdRp are effective against RNA viruses such as hepatitis C virus, and coronaviruses. Thus, the person of ordinary skill in the art would have tested RdRP inhibitor pipendoxifene in a method of inhibiting viral activity of a RNA virus beyond SARS-CoV-2, such as hepatitis C virus, and coronaviruses, including viruses belonging to the corona virus family, as in instant claims 24, 25, with the expectation of achieving therapeutic effect. As such, claims 1, 4-14, 17-26 are rejected as prima facie obvious. Claims 1, 4-14, 17-22, 26 are rejected under 35 U.S.C. 103 as being unpatentable over Hong et al. (J. Microbiology 2021, 59 (2), 124-131, cited in IDS), and Nicola et al. (WO 2021/247601, published 9 December 2021, cited in IDS). Hong et al. (J. Microbiology 2021, 59 (2), 124-131) teach (Abstract) that SERM modulator raloxifene demonstrates efficacy in treating viral infections by influenza A and hepatitis C viruses, which are single stranded RNA viruses of instant claims 1, 4-5, 14, 17-18. Hong teaches (Table 1) SERM modulators raloxifene, bazedoxifene, pipendoxifene. Hong does not teach a method of treating an infection caused by influenza A or hepatitis C viruses, with pipendoxifene, as in the instant claims. Nicola teaches [0536] that raloxifene, bazedoxifene and pipendoxifene are SERMs. Nicola teaches [0533] that Pipendoxifene binds to the viral protein RdRp (EC50 = 8.42 mM). Nicola teaches that RdRp is vital to the viral replication process of all RNA viruses. Nicola is as above. It would have been obvious to a person of ordinary skill in the art to combine the teachings of Hong and Nicola and test pipendoxifene for inhibitory properties against RNA viruses influenza A and hepatitis C. The person of ordinary skill in the art would have been motivated to test pipendoxifene against influenza A or hepatitis C virus, because Hong and Nicola teach that pipendoxifene is a SERM modulator, and Hong teaches that SERM modulator raloxifene demonstrates efficacy in treating viral infections caused by influenza A and hepatitis C viruses. Thus, the person of ordinary skill in the art would have tested SERM modulator pipendoxifene against influenza A or hepatitis C virus, with the expectation that pipendoxifene has antiviral activity against these viruses. Further, the person of ordinary skill in the art would reasonably expected that pipendoxifene inhibits viral replication because Nicola teaches that pipendoxifene is an RdRp inhibitor and RdRp has crucial role in viral replication and in the life cycle of RNA viruses. As such, claims 1, 4-14, 17-22, 26 are rejected as prima facie obvious. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 4-14, 17-26 are provisionally rejected under the judicially created doctrine of obviousness type double patenting as being unpatentable at least over claims 1, 6, 30, 34, 35, 37, 53 of co-pending Application 18/712,214 (cited in PTO-892). Although the conflicting claims are not identical, they are not patentably distinct from each other because claims 1, 6, 30, 34, 35, 37, 53 of co-pending Application 18/712,214 render obvious instant claims. Claims 1, 6, 30, 34, 35, 37, 53 of co-pending Application 18/712,214 are drawn to a method of treating an infection caused by an RNA virus by administering a composition comprising a compound of formula I, II, or III; claim 6 recites pipendoxifene as the compound administered in the method; claim 34 recites that the RNA virus is a positive sense single stranded RNA virus; claim 35 recites a coronavirus; claim 37 recite that influenza, hepatitis C, coronaviruses, which are viruses in the instant claims; claim 53 recites that the composition results in reduction of viral titer of the RNA virus, as in instant claim 13. As such, there is substantial overlap between the method of claims 1, 6, 30, 34, 35, 37, 53 of co-pending Application 18/712,214 and the instant method. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Claims 1, 4-14, 17-26 are rejected under the judicially created doctrine of obviousness type double patenting as being unpatentable over claims 1-11 of U.S. patent 12,551,475, in view of Nicola et al. (WO 2021/247601, published 9 December 2021, cited in IDS). Claims 1-11 of U.S. patent 12,551,475 are drawn to a method for treating an infection or a disease caused by a coronavirus which is SARS-CoV-2, comprising administering to a subject in need thereof a composition comprising pipendoxifene; claim 4 recites that the subject has been exposed to the coronavirus, as in instant claims 6, 19; claim 7 recites that the composition is administered to the subject by intravenous administration, nasal administration, pulmonary administration, oral administration, parenteral administration, or nebulization, as in instant claim 11; claim 8 recites that administrating the composition results in reduction of the viral titer of the virus in the subject, as in instant claim 13. Claims 1-11 of U.S. patent 12,551,475 do not recite a method for treating an infection or a disease caused by a RNA virus which is not SARS-CoV-2, comprising administering to a subject in need thereof a composition comprising pipendoxifene, as in the instant claims. Nicola teaches [0503], Table 6 that pipendoxifene is a RdRP inhibitor for preventing, delaying the onset of, or treating an infection or a disease caused by a RNA virus. Nicola teaches [0533] that Pipendoxifene binds to the viral protein RdRp (EC50 = 8.42 mM). Nicola teaches that RdRp is vital to the viral replication process of all RNA viruses. Nicola teaches [0501] RdRp is a core replication/transcriptional element of all RNA viruses. Nicola teaches that [0502] remdesivir is an antiviral inhibitor of RdRp that has shown to be effective against RNA viruses such as SARS-CoV-2, MERS-CoV and Ebola virus. Nicola teaches that [0502] RdRp’s crucial role in the life cycle of RNA viruses has led to its targeted inhibition for a number of viral infections such as hepatitis C virus, and coronaviruses, which are RNA viruses other than SARS-CoV-2, as in the instant claims 1, 4-5, 14, 17-18. It would have been obvious to a person of ordinary skill in the art to use the teachings of claims 1-11 of U.S. patent 12,551,475 and Nicola, and test pipendoxifene for inhibitory properties against RNA viruses other than SARS-CoV-2. The person of ordinary skill in the art would have been motivated to expand the testing of pipendoxifene against different RNA viruses, beyond SARS-CoV-2, because Nicola teaches that Pipendoxifene binds to the viral protein RdRp which is vital to the viral replication process of all RNA viruses, and Nicola teaches that other inhibitors of RdRp are effective against RNA viruses such as hepatitis C virus, and coronaviruses. Thus, the person of ordinary skill in the art would have tested RdRP inhibitor pipendoxifene in a method of inhibiting viral activity of a RNA virus beyond SARS-CoV-2, such as hepatitis C virus, and coronaviruses, with the expectation of achieving therapeutic effect. Conclusion Claims 1, 4-14, 17-26 are rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to IRINA NEAGU whose telephone number is (571)270-5908. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY S. LUNDGREN can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /IRINA NEAGU/Primary Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Feb 18, 2026
Application Filed
May 13, 2026
Non-Final Rejection mailed — §103, §DP
Jul 01, 2026
Examiner Interview Summary
Aug 12, 2026
Response Filed
Sep 10, 2026
Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12768840
METHOD FOR MONITORING AND PREVENTING CLINICALLY SIGNIFICANT KETONE LEVELS IN PATIENTS RECEIVING DICHLOROACETATE CO-ADMINISTERED WITH A CARBOHYDRATE RESTRICTED DIET
1y 5m to grant Granted Oct 20, 2026
Patent 12751937
STABLE LEVOTHYROXINE COMPOSITIONS IN APROTIC POLAR SOLVENTS
2y 11m to grant Granted Oct 06, 2026
Patent 12740955
Treatment or Prevention of Ischaemic Stroke Reperfusion Injury
4y 3m to grant Granted Sep 22, 2026
Patent 12721828
PHARMACEUTICAL LIQUID COMPOSITION, KIT OF PARTS COMPRISING THE PHARMACEUTICAL LIQUID COMPOSITION, AND METHOD FOR PREPARING THE PHARMACEUTICAL LIQUID COMPOSITION
4y 4m to grant Granted Sep 01, 2026
Patent 12685721
AEROSOL COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
3y 11m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
47%
Grant Probability
99%
With Interview (+57.2%)
2y 9m (~2y 0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 720 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month